Parameters for monitoring treatment effects in CIDP with anti-MAG/SGPG IgMantibody

We used cycles of plasma Exchange and intravenous cyclophosphamide to treat a patient who had chronic inflammatory demyelinating polyneuropathy with a nti-myelin-associated gLycoprotein/sulfoglucuronylparagioboside IgM antibod y. After treatment, serum anti-sulfoglucuronylparagloboside IgM antibody ti ters were reduced significantly, and clear symptomatic improvement followed . The percentage of CD57-positive lymphocytes and natural killer cell activ ity had also returned to normal. Our findings indicate that serial measurem ents of these parameters are useful for monitoring treatment effect in this disease. (C) 2001 John Wiley & Sons, Inc.